The Oregonian highlights the widespread difficulty of getting timely appointments with primary care clinicians. Jane Zhu, M.D., says, “Access challenges are cutting across populations, across income distributions, across geographies … This is not a segmented issue. This is a systemic problem.”

Media cover the ongoing and growing hantavirus outbreak originating from a cruise ship. Bill Messer, M.D., Ph.D., says, “We need to watch and not be dismissive of symptoms or the risk to people sitting close to people on airplanes, things like that, because we really just don’t know.”

OPB Think Out Loud highlights new research that has linked tinnitus with elevated serotonin levels in certain regions of the brain. Larry Trussell, Ph.D., says, “When you have a condition, you can empathize with others. So, in a way, you could say tinnitus has been a gift to me, because now I have a way to relate to this patient population and it made it one of my missions in my research career.”

Women’s Wear Daily spotlights the Air Jordan 3 Retro Doernbecher XIX sneakers, which appeared in the Apple TV series ‘Shrinking.’

Gleevec, the first medication that specifically targets cancer cells, gained FDA approval 25 years ago, turning a lethal leukemia into a manageable illness. The creator of the medication, Brian Druker, M.D., says, “It’s been the honor of my life to fight for my patients and to see Gleevec give hundreds of thousands of people their lives back.”

Gleevec, the first medication that specifically targets cancer cells, gained FDA approval 25 years ago, turning a lethal leukemia into a manageable illness. The creator of the medication, Brian Druker, M.D., says, “It’s been the honor of my life to fight for my patients and to see Gleevec give hundreds of thousands of people their lives back.”

Gleevec, the first medication that specifically targets cancer cells, gained FDA approval 25 years ago, turning a lethal leukemia into a manageable illness. The creator of the medication, Brian Druker, M.D., says, “It’s been the honor of my life to fight for my patients and to see Gleevec give hundreds of thousands of people their lives back.”

ScienceAlert covers a 2025 OHSU study that suggests insufficient sleep may shorten your life. Andrew McHill, Ph.D., says, “We've always thought sleep is important, but this research really drives that point home: People really should strive to get seven to nine hours of sleep if at all possible.”

Becker’s Hospital Review mentions the OHSU Knight Cancer Institute in a roundup of hospitals spending more than $4 billion in cancer care service expansions to expand capacity, decentralize access and sustain the next generation of oncology care.

OHSU Scientists developed a new way to detect early signs of pancreatic cancers, using a small electronic jolt on a microchip to collect nanoparticles shed by tumors into blood. Stuart Ibsen, Ph.D., says, “Whatever biomarkers the tumor has are carried on these little particles… Our technology allows us to detect those particles.”